Randall J Mack
Overview
Explore the profile of Randall J Mack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berkowitz R, Steinfeld R, Sah A, Mack R, McCallum S, Du W, et al.
Pain Med
. 2021 Jan;
22(6):1261-1271.
PMID: 33502533
Objective: To evaluate the effect of perioperative meloxicam IV 30 mg on opioid consumption in primary total knee arthroplasty (TKA). Design: Multicenter, randomized, double-blind, placebo-controlled trial. Subjects: In total, 181...
2.
Berkowitz R, Mack R, McCallum S
Pain Manag
. 2020 Dec;
11(3):249-258.
PMID: 33291975
Meloxicam for intravenous use (meloxicam iv.) is a nanocrystal formulation with improved dissolution properties and shortened time to peak plasma concentrations versus oral meloxicam. In Phase III and IIIb trials,...
3.
Silinsky J, Marcet J, Anupindi V, Karkare S, Shah D, Mack R, et al.
Pain Manag
. 2020 Oct;
11(1):9-21.
PMID: 33094682
Evaluate safety/efficacy of intravenous meloxicam in a colorectal enhanced recovery after surgery protocol. Adults undergoing primary open or laparoscopic colorectal surgery with bowel resection and/or anastomosis received meloxicam IV 30 ...
4.
Sharpe K, Berkowitz R, Tyndall W, Boyer D, McCallum S, Mack R, et al.
J Pain Res
. 2020 Feb;
13:221-229.
PMID: 32021411
Objective: A Phase 3 randomized multicenter, double-blind, placebo-controlled trial (NCT02720692) compared once-daily intravenous (IV) meloxicam 30 mg to placebo, when added to the standard of care pain management regimens, in...
5.
Rechberger T, Mack R, McCallum S, Du W, Freyer A
Anesth Analg
. 2019 May;
128(6):1309-1318.
PMID: 31094806
Background: An intravenous (IV) formulation of meloxicam was developed for moderate-to-severe pain management. This study evaluated the safety and efficacy of meloxicam IV after open abdominal hysterectomy. Meloxicam IV is...
6.
Bergese S, Melson T, Candiotti K, Ayad S, Mack R, McCallum S, et al.
Clin Pharmacol Drug Dev
. 2019 Feb;
8(8):1062-1072.
PMID: 30786162
An intravenous (IV) formulation of meloxicam is being studied for moderate to severe pain management. This phase 3, randomized, multicenter, double-blind, placebo-controlled trial evaluated the safety of once-daily meloxicam IV...
7.
Viscusi E, Gan T, Bergese S, Singla N, Mack R, McCallum S, et al.
Reg Anesth Pain Med
. 2019 Feb;
44(3):360-368.
PMID: 30737315
Background And Objectives: To describe the safety and tolerability of intravenous meloxicam compared with placebo across all phase II/III clinical trials. Methods: Safety data and opioid use from subjects with...
8.
Singla N, Bindewald M, Singla S, Leiman D, Minkowitz H, McCallum S, et al.
Plast Reconstr Surg Glob Open
. 2018 Oct;
6(6):e1846.
PMID: 30276064
Background: A nanocrystal intravenous (IV) formulation of meloxicam is being studied with the aim of providing postoperative analgesia. Methods: This randomized, multicenter, double-blind, placebo-controlled trial evaluated meloxicam IV 30 mg...
9.
Singla N, McCallum S, Mack R, Freyer A, Hobson S, Du W
J Pain Res
. 2018 Oct;
11:1901-1903.
PMID: 30271196
No abstract available.
10.
Pollak R, Gottlieb I, Hakakian F, Zimmerman J, McCallum S, Mack R, et al.
Clin J Pain
. 2018 Mar;
34(10):918-926.
PMID: 29554032
Objective: To evaluate the analgesic efficacy and safety of a novel intravenous (IV) formulation of meloxicam (30 mg) in patients with moderate-to-severe pain following a standardized, unilateral bunionectomy with first...